

(PB3674) PROSPECTIVE EXPLORATION OF ZUBERITAMAB, LENALIDOMIDE COMBINED WITH ORELABRUTINIB (HRO) IN THE TREATMENT OF NEWLY DIAGNOSED MARGINAL ZONE LYMPHOMA.

Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical

Yu Qiu^{*1}, Chunxia Zhang¹, Min Wang¹, Yayue Gao¹, Qianqian Ju¹, Chao Guo¹, Yuan Huang¹, Jingya Wang¹, Yang Li¹, Zi-Xian Liu¹, Ming Gong¹, Zhenling Li¹

¹China-Japan Friendship Hospital, Beijing, China;

Background

Marginal zone lymphoma (MZL) is a common B-cell non-Hodgkin lymphoma. Due to the high heterogeneity of MZL, there is no clear standard treatment regimen.

Aims

This study aims to prospectively explore the efficacy and safety of a novel chemotherapy-free regimen combining the new CD20 monoclonal antibody zuberitamab, lenalidomide, and orelabrutinib (HRO) as a first-line treatment in newly diagnosed MZL patients with treatment indications at the China-Japan Friendship Hospital starting from Sep 2025.

Methods

Eligible patients were adults aged ≥ 18 years with histologically confirmed newly diagnosed MZL. The treatment regimen includes 375mg/m² zuberitamab on days 1, 8, and 15 of the first cycle, followed by 375mg/m² zuberitamab on day 1 from the second cycle, lenalidomide 25mg on days 1-14, and orelabrutinib 150mg qd continuously orally, administered every 21 days for a total of 8 cycles. Subjects achieving PR or better after treatment will receive orelabrutinib monotherapy maintenance for a total of 2 years. The primary endpoint is the complete response rate (CRR), and secondary endpoints include overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Safety is assessed by monitoring adverse events (AE).

Results

A total of 7 patients have been included in this study, with males accounting for 71.4% (5/7). The median age at diagnosis is 78 years (range 48-84). All 7 patients have mucosa-associated lymphoid tissue extranodal marginal zone lymphoma (MALT), with the main affected sites including the lung, intestine, and orbit. Among them, 1 patient has large cell transformation, 5 patients (71.4%) are at Ann Arbor stage IV, 42.9% of the patients have an MZL-IPI score of 1, and 42.9% have an MZL-IPI score of 2. Median treatment of 5 cycles (2-7), 5 patients were evaluable for efficacy, ORR was 80%, with 20.0% (1/5) achieving CR, median OS and PFS were not reached. 57.1% (4/7) of patients experienced AE, all were graded 1-2, common AEs included rash, liver function impairment, lymphocyte reduction. No atrial fibrillation or bleeding related to BTK inhibitors occurred.

Summary/Conclusion

The HRO regimen as first-line treatment for MZL, especially in elderly patients with high-risk features, is a safe and effective treatment strategy, and future research updates will include more follow-up data.

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. **Abstract Book Citations:** Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the "Author Information" page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.